This map shows the geographic impact of A Harłozińska's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A Harłozińska with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A Harłozińska more than expected).
This network shows the impact of papers produced by A Harłozińska. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A Harłozińska. The network helps show where A Harłozińska may publish in the future.
Co-authorship network of co-authors of A Harłozińska
This figure shows the co-authorship network connecting the top 25 collaborators of A Harłozińska.
A scholar is included among the top collaborators of A Harłozińska based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with A Harłozińska. A Harłozińska is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Harłozińska, A, P Sedlaczek, J Kulpa, et al.. (2004). Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma.. PubMed. 24(2C). 1149–57.35 indexed citations
Bar, Julia, et al.. (2001). Relations between the expression of p53, c-erbB-2, Ki-67 and HPV infection in cervical carcinomas and cervical dysplasias.. PubMed. 21(2A). 1001–6.15 indexed citations
Bar, Julia & A Harłozińska. (2000). Morphological and phenotypic characterization of a new established ovarian carcinoma cell line (OvBH-1).. PubMed. 20(5A). 2975–80.8 indexed citations
7.
Bębenek, Marek, et al.. (1998). Prospective studies of p53 and c-erbB-2 expression in relation to clinicopathological parameters of human ductal breast cancer in the second stage of clinical advancement.. PubMed. 18(1B). 619–23.16 indexed citations
8.
Harłozińska, A, et al.. (1998). Expression of epidermal growth factor receptor family proteins (EGFR, c-erbB-2 and c-erbB-3) in gastric cancer and chronic gastritis.. PubMed. 18(4A). 2727–32.46 indexed citations
9.
Harłozińska, A, et al.. (1998). p53, c-erbB-2 and p21ras expression in tumor effusion cells of patients with histopathologically different ovarian neoplasms.. PubMed. 17(5A). 3545–52.6 indexed citations
10.
Harłozińska, A, et al.. (1998). TPS and CA 125 levels in serum, cyst fluid and ascites of patients with epithelial ovarian neoplasms.. PubMed. 17(6D). 4473–8.18 indexed citations
11.
Harłozińska, A, et al.. (1997). Relationship between c-erbB-2 oncoprotein, epidermal growth factor receptor, and estrogen receptor expression in patients with ductal breast carcinoma. Association with tumor phenotypes.. PubMed. 10(2). 217–22.17 indexed citations
Harłozińska, A, et al.. (1992). In vitro effects of Chelidonium majus L. alkaloid thiophosphoric acid conjugates (Ukrain) on the phenotype of normal human lymphocytes.. PubMed. 18(1). 17–21.2 indexed citations
14.
Harłozińska, A, et al.. (1992). Density distribution and immunological reactivity of tumor cells from peritoneal effusions of patients with ovarian neoplasms.. PubMed. 4(1). 1–12.5 indexed citations
15.
Harłozińska, A, et al.. (1991). CEA and NCA levels in peripheral and tumour venous blood of patients with gastric and colonic carcinomas estimated by RIA and EIA methods.. PubMed. 17(1). 59–64.8 indexed citations
Michalak, T.I., et al.. (1983). Localization of carcinoembryonic antigen in mesenteric lymph nodes of patients with gastrointestinal cancer.. PubMed. 30(1). 67–72.1 indexed citations
19.
Harłozińska, A, et al.. (1983). Antigenic heterogeneity of human lung cancers.. PubMed. 70(3). 427–33.7 indexed citations
20.
Albert, Z, J Bręborowicz, A Harłozińska, et al.. (1978). Reagents for radioimmunological determination of carcinoembryonic antigen (CEA).. PubMed. 26(1-6). 227–9.1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.